Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
10 studies found for:    "Corticobasal degeneration"
Show Display Options
Rank Status Study
1 Completed
Has Results
A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration
Conditions: Progressive Supranuclear Palsy;   Corticobasal Degeneration
Intervention: Drug: Lithium
2 Completed Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration
Conditions: Progressive Supranuclear Palsy;   Corticobasal Degeneration;   Parkinsonism
3 Completed Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers
Conditions: Progressive Supranuclear Palsy;   Corticobasal Degeneration
Interventions: Drug: 18F-AV-1451;   Drug: florbetapir F18
4 Active, not recruiting 4 Repeat Tauopathy Neuroimaging Initiative
Conditions: Progressive Supranuclear Palsy;   Corticobasal Degeneration
Intervention: Other: Observational Study
5 Active, not recruiting Defining Phenotypes of Movement Disorders :Parkinson's Plus Disorders, PD,Essential Tremor, (ET),Cortical Basal Degeneration, (CBD),Multiple Systems Atrophy (MSA), Magnetoencephalography
Conditions: Essential Tremor;   Multiple System Atrophy;   Corticobasal Degeneration;   Supranuclear Palsy, Progressive
6 Active, not recruiting Davunetide (AL-108) in Predicted Tauopathies - Pilot Study
Conditions: Predicted Tauopathies, Including:;   Progressive Supranuclear Palsy;   Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17;   Corticobasal Degeneration Syndrome;   Progressive Nonfluent Aphasia
Interventions: Drug: davunetide (AL-108, NAP);   Drug: Placebo nasal spray
7 Recruiting PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK
Conditions: Progressive Supranuclear Palsy (PSP);   Corticobasal Degeneration;   Multiple System Atrophy (MSA)
8 Recruiting Genetic Characterization of Movement Disorders and Dementias
Conditions: Ataxia;   Dystonia;   Parkinson's Disease;   Amyotrophic Lateral Sclerosis;   Corticobasal Degeneration;   Multiple System Atrophy;   Alzheimer's Disease;   Lewy Body Dementia
9 Recruiting Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)
Conditions: FTLD;   Progressive Supranuclear Palsy (PSP);   Frontotemporal Dementia (FTD);   Corticobasal Degeneration (CBD);   PPA Syndrome;   Behavioral Variant Frontotemporal Dementia (bvFTD);   Semantic Variant Primary Progressive Aphasia (svPPA);   Nonfluent Variant Primary Progressive Aphasia (nfvPPA);   FTD With Amyotrophic Lateral Sclerosis (FTD/ALS);   Amyotrophic Lateral Sclerosis (ALS);   Oligosymptomatic PSP (oPSP);   Corticobasal Syndrome (CBS)
10 Recruiting Safety Study of TPI-287 to Treat CBS and PSP
Conditions: Primary Four Repeat Tauopathies (4RT);   Corticobasal Syndrome (CBS);   Progressive Supranuclear Palsy (PSP);   Corticobasal Degeneration (CBD)
Interventions: Drug: TPI 287 2 mg/m2;   Drug: TPI-287 20 mg/m2;   Drug: Placebo;   Drug: TPI-287 6.3 mg/m2

Indicates status has not been verified in more than two years